Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.
10.1007/s11596-012-0067-x
- Author:
Dong YANG
1
;
Teng HOU
;
Xiong YANG
;
Yan MA
;
Longwang WANG
;
Bing LI
Author Information
1. Department of Urology, Huazhong University of Science and Technology, Wuhan, China. yangdd2007@163.com
- Publication Type:Journal Article
- MeSH:
Animals;
Atrophy;
pathology;
physiopathology;
Disease Models, Animal;
Gonadotropin-Releasing Hormone;
analogs & derivatives;
antagonists & inhibitors;
Hormone Antagonists;
Humans;
Male;
Organ Size;
drug effects;
Prostatic Hyperplasia;
chemically induced;
pathology;
physiopathology;
Proto-Oncogene Proteins c-myc;
metabolism;
Rats;
Rats, Sprague-Dawley;
Transforming Growth Factor beta1;
metabolism
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2012;32(3):389-395
- CountryChina
- Language:English
-
Abstract:
In the present study, we investigated the roles of TGF-β signaling pathway in a rat benign prostatic hyperplasia (BPH) model treated with cetrorelix. TGF-β1 and c-Myc expression were measured by qRT-PCR and Western blotting in the proximal and distal region of ventral prostatic lobes, respectively. We observed that treatment with cetrorelix led to a significant reduction of ventral prostate weight in a dose-dependent manner. In the proximal region, after cetrorelix treatment, the expression of TGF-β1 was dramatically increased (P<0.05), while the expression of c-Myc was significantly decreased (P<0.05). In comparison with the control group, the cetrorelix groups had more TUNEL-positive cells. Our findings strongly suggest that the TGF-β signaling pathway may be one of the major causes responsible for prostate volume reduction in BPH rats after cetrorelix treatment.
